Resource Library

Discover Kymera’s research and resources on our exciting platform, pipeline, and additional cutting-edge technologies.

  • Programs & Targets

  • Indications

  • Year

  • Resource Type/Format

  • Development Stage

Related Resources

March 8, 2024

Potent and Selective Oral STAT6 Degraders Inhibit IL-4 and IL-13 Functions in Human Cells and Block TH2 Inflammation in a Mouse Model of Atopic Dermatitis

American Academy of Dermatology (AAD) 2024 Annual Meeting
Read More
March 8, 2024

Potent and Selective TYK2 degraders, Devoid of JAK Activity, Potently and Completely Suppress IL12/23 and Type I IFN Signaling Pathways

American Academy of Dermatology (AAD) 2024 Annual Meeting
Read More
November 14, 2023

IRAK4 Degradation vs Inhibition

IRAK4 Program Background
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
Read More
November 13, 2023

Nature Medicine: IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial

Lindsay Ackerman, Gerard Acloque, Sandro Bacchelli, Howard Schwartz, Brian J. Feinstein, et al.
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
Read More
August 16, 2023

Discovery of KT-474, a potent, selective, and orally bioavailable IRAK4 degrader for the treatment of autoimmune diseases

American Chemical Society (ACS) Fall 2023 Meeting
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
Read More
May 18, 2023

Safety and Efficacy of IRAK4 Degrater KT-474 (SAR444656) for Hidradenitis Suppurativa and Atopic Dermatitis

European Academy of Dermatology & Venereology (EADV) Symposium 2023
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
Read More
October 26, 2022

The Phase 1 Healthy Volunteer Clinical Trial of KT-474

5th Annual Targeted Protein Degradation (TPD) Summit
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
Read More
October 26, 2022

Development and Performance of Pharmacodynamic Assays to Demonstrate Proof-of-Mechanism for IRAK4 Degraders in a Phase1 Study

5th Annual Targeted Protein Degradation (TPD) Summit
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
Read More
July 28, 2022

Utilizing degraders to Modulate B & T Cell Targets for Autoimmune Diseases

3rd B&T Cell-Mediated Autoimmune Disease Drug Development
Read More
May 31, 2022

STAT3 degraders inhibit Th17 development and cytokine production resulting in profound inhibition of collagen-induced autoimmune murine arthritis

European Alliance of Associations for Rheumatology (EULAR) 2022 Annual Congress
Read More